ClearPoint Neuro, Inc. (CLPT) reported second-quarter 2026 revenue of $10.9 million, up 18.1% from a year earlier, while gross profit rose 20.8% to $6.7 million. The company’s performance improved at the top line, but profitability remained under pressure.
Operating loss widened to $10.2 million, and net loss attributable to common shareholders increased to $11.3 million. Diluted loss per share came in at $0.38, compared with an estimated loss of $0.29.
Cash used in operating activities totaled $7.0 million, and cash and cash equivalents stood at $29.4 million. Total liabilities rose to $76.0 million, reflecting a year-over-year increase in leverage.
Key figures included:
The stock fell 20.67% after the market close following the release.
Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.
ClearPoint Neuro, Inc. Insider Trading Activity
ClearPoint Neuro, Inc. insiders have traded $CLPT stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $CLPT stock by insiders over the last 6 months:
- JOSEPH BURNETT (CEO and President) has made 0 purchases and 4 sales selling 101,794 shares for an estimated $1,790,720.
- MATTHEW B. KLEIN sold 16,000 shares for an estimated $185,440
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
ClearPoint Neuro, Inc. Hedge Fund Activity
We have seen 61 institutional investors add shares of ClearPoint Neuro, Inc. stock to their portfolio, and 38 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MAK CAPITAL ONE LLC added 1,901,489 shares (+inf%) to their portfolio in Q1 2026, for an estimated $17,303,549
- SG AMERICAS SECURITIES, LLC added 372,356 shares (+inf%) to their portfolio in Q1 2026, for an estimated $3,388,439
- MILLENNIUM MANAGEMENT LLC removed 283,401 shares (-55.0%) from their portfolio in Q1 2026, for an estimated $2,578,949
- BALYASNY ASSET MANAGEMENT L.P. removed 217,274 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $1,977,193
- PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. removed 180,525 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $1,642,777
- GOLDMAN SACHS GROUP INC added 173,273 shares (+59.7%) to their portfolio in Q1 2026, for an estimated $1,576,784
- TUDOR INVESTMENT CORP ET AL added 156,971 shares (+inf%) to their portfolio in Q1 2026, for an estimated $1,428,436
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
ClearPoint Neuro, Inc. Price Targets
Multiple analysts have issued price targets for $CLPT recently. We have seen 2 analysts offer price targets for $CLPT in the last 6 months, with a median target of $25.0.
Here are some recent targets:
- Anderson Schock from B. Riley Securities set a target price of $30.0 on 06/18/2026
